Advertisement

A rare case of Pseudomonas aeruginosa enteritis induced by pembrolizumab

Published:September 14, 2022DOI:https://doi.org/10.1016/j.anl.2022.09.004

      Abstract

      A 72-year-old male had pseudomonal enteritis related to pembrolizumab. Chemotherapy for hypopharyngeal carcinoma with lung metastasis comprised cisplatin, 5-FU, and pembrolizumab. On day 14 of chemotherapy treatment he had a sudden prominent abdominal bulge, decreased consciousness, and drop in blood pressure in septic shock. CT scan showed marked intestinal gas through to intrahepatic bile ducts. Pseudomonas aeruginosa was simultaneously detected in both blood and stool cultures. Intestinal endoscopy revealed ulcerative lesions from the transverse colon to the rectum. Pathological investigations indicated apoptosis of the villus. The patient was diagnosed with pseudomonal enteritis induced by immune-related adverse events from the use of pembrolizumab. Treatment by corticosteroid and meropenem were subsequently switched to cefepime and metronidazole, and this successfully improved his colitis. In this new era of biological-targeted drugs and as clinical experience grows, we recommend a high level of alertness for potential diagnosis of infectious complications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Auris Nasus Larynx
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Redelman-Sidi G
        • Michielin O
        • Cervera C
        • Ribi C
        • Aguado JM
        • Fernández-Ruiz M
        • et al.
        ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
        Clin Microbiol Infect. 2018; (24 Suppl 2Suppl[PubMed:29427804]): S95-s107https://doi.org/10.1016/j.cmi.2018.01.030
        • Kok VC.
        Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
        Front Oncol. 2020; 10 ([PubMed:32185135]): 268https://doi.org/10.3389/fonc.2020.00268
        • Burtness B
        • Harrington KJ
        • Greil R
        • Soulières D
        • Tahara M
        • de Castro Jr., G
        • et al.
        Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
        Lancet. 2019; 394 ([PubMed:31679945]): 1915-1928https://doi.org/10.1016/s0140-6736(19)32591-7
        • Khoja L
        • Day D
        • Wei-Wu Chen T
        • Siu LL
        • Hansen AR
        Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
        Ann Oncol. 2017; 28 ([PubMed:28945858]): 2377-2385https://doi.org/10.1093/annonc/mdx286
        • Del Castillo M
        • Romero FA
        • Argüello E
        • Kyi C
        • Postow MA
        Redelman-Sidi G. The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
        Clin Infect Dis. 2016; 63 ([PubMed:27501841]): 1490-1493https://doi.org/10.1093/cid/ciw539
        • Sisman G
        • Barbur E
        • Saka D
        Erdamar Cetin S. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.
        Cancer Immunol Immunother. 2021; 70 ([PubMed:33481043]): 2385-2388https://doi.org/10.1007/s00262-020-02815-1
        • Haanen J
        • Carbonnel F
        • Robert C
        • Kerr KM
        • Peters S
        • Larkin J
        • et al.
        Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2018; 29 (Suppliv264-iv6[PubMed:29917046])https://doi.org/10.1093/annonc/mdy162
        • Gopalakrishnan V
        • Spencer CN
        • Nezi L
        • Reuben A
        • Andrews MC
        • Karpinets TV
        • et al.
        Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
        Science. 2018; 359 ([PubMed:29097493]): 97-103https://doi.org/10.1126/science.aan4236
        • Matson V
        • Fessler J
        • Bao R
        • Chongsuwat T
        • Zha Y
        • Alegre ML
        • et al.
        The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
        Science. 2018; 359 ([PubMed:29302014]): 104-108https://doi.org/10.1126/science.aao3290
        • Picchi H
        • Mateus C
        • Chouaid C
        • Besse B
        • Marabelle A
        • Michot JM
        • et al.
        Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.
        Clin Microbiol Infect. 2018; 24 ([PubMed:29269089]): 216-218https://doi.org/10.1016/j.cmi.2017.12.003
        • Kyi C
        • Hellmann MD
        • Wolchok JD
        • Chapman PB
        • Postow MA.
        Opportunistic infections in patients treated with immunotherapy for cancer.
        J Immunother Cancer. 2014; 2 ([PubMed:24991413]): 19https://doi.org/10.1186/2051-1426-2-19
        • Uchida N
        • Fujita K
        • Nakatani K
        • Mio T.
        Acute progression of aspergillosis in a patient with lung cancer receiving nivolumab.
        Respirol Case Rep. 2018; 6 ([PubMed:29321933]): e00289https://doi.org/10.1002/rcr2.289
        • Porco FV
        • Visconte EB.
        Pseudomonas aeruginosa as a cause of infectious diarrhea successfully treated with oral ciprofloxacin.
        Ann Pharmacother. 1995; 29 ([PubMed:8573957]): 1122-1123https://doi.org/10.1177/106002809502901110
        • Adlard PA
        • Kirov SM
        • Sanderson K
        • Cox GE.
        Pseudomonas aeruginosa as a cause of infectious diarrhoea.
        Epidemiol Infect. 1998; 121 ([PubMed:9747778]): 237-241https://doi.org/10.1017/s095026889800106x
        • Iguidbashian JP
        • Parekh JD
        • Kukrety S
        • Andukuri VG.
        Campylobacter jejuni and Pseudomonas coinfection in the setting of ulcerative colitis.
        BMJ Case Rep. 2018; 2018 ([PubMed:29880626])https://doi.org/10.1136/bcr-2018-224941
        • Nagasaki A
        • Takahashi H
        • Iinuma M
        • Uchiyama T
        • Watanabe S
        • Koide T
        • et al.
        Ulcerative colitis with multidrug-resistant Pseudomonas aeruginosa infection successfully treated with bifidobacterium.
        Digestion. 2010; 81 ([PubMed:20090336]): 204-205https://doi.org/10.1159/000236042
        • Kim SW
        • Peck KR
        • Jung SI
        • Kim YS
        • Kim S
        • Lee NY
        • et al.
        Pseudomonas aeruginosa as a potential cause of antibiotic-associated diarrhea.
        J Korean Med Sci. 2001; 16 ([PubMed:11748355]): 742-744https://doi.org/10.3346/jkms.2001.16.6.742
        • Morita H
        • Murata Y
        • Yamamoto M
        • Kobori O
        • Nozato H.
        Pseudomonas aeruginosa-induced toxic enteritis (Pseudomonas enteritis) in a postoperative patient with sigmoid colon cancer and bronchiectasis associated with antibiotic and H2-blocker administration.
        Am J Gastroenterol. 1995; 90 ([PubMED: 7639268]): 1370
        • Gunduz M
        • Murakami D
        • Gunduz I
        • Tamagawa S
        • Hiraoka M
        • Sugita G
        • et al.
        Recurrent bacterial translocation from gut and sepsis in Head and neck cancer patients and its prevention by probiotics.
        Med Hypotheses. 2018; 120 ([PubMed:30220331]): 124-127https://doi.org/10.1016/j.mehy.2018.08.020
        • Oltolini C
        • Ripa M
        • Andolina A
        • Brioschi E
        • Cilla M
        • Petrella G
        • et al.
        Invasive Pulmonary Aspergillosis Complicated by Carbapenem-Resistant Pseudomonas aeruginosa Infection During Pembrolizumab Immunotherapy for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature.
        Mycopathologia. 2019; 184 ([PubMed:30101407]): 181-185https://doi.org/10.1007/s11046-018-0291-4
        • Weber JS
        • Hodi FS
        • Wolchok JD
        • Topalian SL
        • Schadendorf D
        • Larkin J
        • et al.
        Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.
        J Clin Oncol. 2017; 35 ([PubMed:28068177]): 785-792https://doi.org/10.1200/jco.2015.66.1389